185 related articles for article (PubMed ID: 31903939)
1. [Description of the French players from Avenir's investment program: the role of MabDesign].
Groux N; Pontremoli R; Vuddamalay G; Richard G; Pons D
Med Sci (Paris); 2019 Dec; 35(12):1198-1201. PubMed ID: 31903939
[No Abstract] [Full Text] [Related]
2. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
Romagné F
Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
[No Abstract] [Full Text] [Related]
3. [The Antibody Club of the French Society of Immunology: structuring the assets of French research].
Larivière M; Monteiro R
Med Sci (Paris); 2019 Dec; 35(12):1206-1207. PubMed ID: 31903942
[No Abstract] [Full Text] [Related]
4. ESDR 2010-2020: Journey toward Translational and Systems Dermatology.
Schmuth M; Biedermann T; Picardo M; Florestan T; Barker J
J Invest Dermatol; 2020 Sep; 140(9S):S167-S170. PubMed ID: 32800164
[No Abstract] [Full Text] [Related]
5. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
Pécoul B
Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
[No Abstract] [Full Text] [Related]
6. [The RARE 2017 meeting for companies developing products for rare patients].
Ferry A
Med Sci (Paris); 2018 May; 34 Hors série n°1():7. PubMed ID: 29911542
[No Abstract] [Full Text] [Related]
7. [Research in respiratory health in 2019: some breath to energize your research].
Vachier I; Bonniaud P; Maitre B; Roche N; Similowski T
Rev Mal Respir; 2020 Mar; 37(3):191-192. PubMed ID: 32115293
[No Abstract] [Full Text] [Related]
8. CYTO Innovation: Inspiring and Supporting Innovators in ISAC.
Holden E; Smith PJ
Cytometry A; 2019 Apr; 95(4):411-415. PubMed ID: 30882998
[No Abstract] [Full Text] [Related]
9. [A dream becoming reality].
Pouget J
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():7. PubMed ID: 30943152
[No Abstract] [Full Text] [Related]
10. Autophagy, Inflammation, and Metabolism (AIM) Center in its second year.
Deretic V; Prossnitz E; Burge M; Campen MJ; Cannon J; Liu KJ; Liu M; Hall P; Sklar LA; Allers L; Mariscal L; Garcia SA; Weaver J; Baehrecke EH; Behrends C; Cecconi F; Codogno P; Chen GC; Elazar Z; Eskelinen EL; Fourie B; Gozuacik D; Hong W; Jo EK; Johansen T; Juhász G; Kimchi A; Ktistakis N; Kroemer G; Mizushima N; Münz C; Reggiori F; Rubinsztein D; Ryan K; Schroder K; Shen HM; Simonsen A; Tooze SA; Vaccaro M; Yoshimori T; Yu L; Zhang H; Klionsky DJ
Autophagy; 2019 Oct; 15(10):1829-1833. PubMed ID: 31234750
[TBL] [Abstract][Full Text] [Related]
11. ESDR around the Millennium Change.
Bruckner-Tuderman L
J Invest Dermatol; 2020 Sep; 140(9S):S158-S159. PubMed ID: 32800160
[No Abstract] [Full Text] [Related]
12. The History and Future Prospects of ISID: A European Perspective.
Reynolds NJ; Enk AH
J Invest Dermatol; 2020 Sep; 140(9S):S178-S180. PubMed ID: 32800168
[No Abstract] [Full Text] [Related]
13. [A word from the coordinators].
Pèlegrin A; Beck A; Watier H
Med Sci (Paris); 2019 Dec; 35(12):923. PubMed ID: 31903894
[No Abstract] [Full Text] [Related]
14. Women in Leadership and Scientific Development of the ESDR.
Leigh IM; Zambruno G
J Invest Dermatol; 2020 Sep; 140(9S):S160-S162. PubMed ID: 32800161
[No Abstract] [Full Text] [Related]
15. [Needs for more R&D in the field of rare diseases].
Tiennot-Herment L
Med Sci (Paris); 2018 May; 34 Hors série n°1():48-49. PubMed ID: 29911563
[No Abstract] [Full Text] [Related]
16. [The long path (s) of placing medicines on the market].
Duguet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
[No Abstract] [Full Text] [Related]
17. The Australian Society for Immunology in the 1990s and beyond.
Shellam GR
Immunol Cell Biol; 1991 Oct; 69 ( Pt 5)():323-5. PubMed ID: 1787002
[No Abstract] [Full Text] [Related]
18. [Fiftieth anniversary of the French Society for Connective Tissue Research].
Robert L; Labat-Robert J; Michel Robert A
Biol Aujourdhui; 2012; 206(2):69-72. PubMed ID: 22748044
[TBL] [Abstract][Full Text] [Related]
19. [Fight against COVID-19: market overview and pipeline of ongoing trials].
Pontremoli R; Richard G; Vuddamalay G; Groux N
Med Sci (Paris); 2020 Dec; 36(12):1225-1232. PubMed ID: 33211647
[No Abstract] [Full Text] [Related]
20. Reviving an R&D pipeline: a step change in the Phase II success rate.
Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
